LLR ICB Position Statement Patient Self-Testing of INR for warfarin monitoring(123 KB)
Date added: 2nd Sep 2026
| Drug Name | Classification | Clinical Indication | Comments |
|---|---|---|---|
| ACAMPROSATE | Yellow | Alcohol dependence |
There is currently no commissioned service within general practice to support the prescribing and ongoing management of this treatment. There are, though, potential clinical benefits in the maintenance of abstinence from alcohol (and these patients are likely to have been discharged from specialist services as they are no longer drinking alcohol), so where a clinician has the appropriate expertise and feels clinically competent to do so, they may choose to prescribe. However, there is no contractual requirement or expectation for GPs to initiate or continue prescribing, and practices are not obligated to issue these prescriptions. |
| CENOBAMATE (Ontozry®) (UPDATED) | Yellow | Focal onset seizures in epilepsy |
In line with NICE TA753 |
| CLESROVIMAB (NEW) | Red | RSV passive immunisation as per green book | |
| DONEPEZIL (UPDATED) | Yellow | Alzheimer's disease |
In line with NICE NG 97 Orodispersible tablets are more cost-effective than the oral solution. However, Apozyl® 5mg remains more cost-effective in primary care. |
| DULAGLUTIDE (Trulicity®) | Green | Type 2 diabetes |
Conditional on prescriber being trained to select and train patients – use in conjunction with updated NICE NG28. Once a week preparation. |
| HYDROCORTISONE MR CAPSULES (Efmody®) (NEW) | Red | for congenital adrenal hyperplasia (CAH) in adolescents aged 12 years to 17 years when immediate release glucocorticosteroids not tolerated/ unsuitable | |
| HYDROXYCHLOROQUINE (UPDATED) | Yellow | Dermatological conditions |
Retinal screening for hydroxychloroquine toxicity should be arranged in line with Royal College of Ophthalmologists guidance. Secondary care is responsible for ensuring appropriate monitoring is arranged. |
| HYDROXYCHLOROQUINE (UPDATED) | Yellow | Rheumatological disease |
Retinal screening for hydroxychloroquine toxicity should be arranged in line with Royal College of Ophthalmologists guidance. Secondary care is responsible for ensuring appropriate monitoring is arranged. |
| LENACAPAVIR (Sunlenca®) (UPDATED) | Red | multi-drug resistant HIV | |
| LIRAGLUTIDE (Diavic®) | Yellow | Type 2 diabetes mellitus in children 10 years and over |
Diavic® is the preferred liraglutide formulation across LLR Available only in line with NICE NG28 |
| LIRAGLUTIDE (Diavic®) (UPDATED) | Yellow | Type 2 diabetes |
Diavic® is the preferred liraglutide formulation across LLR. Available only in line with NICE NG28 |
| METHYLPHENIDATE (UPDATED) | Orange | Attention deficit hyperactivity disorder (ADHD)- prescribe CR formulation by brand name only |
For information about products please see relevant Shared Care and Net Formulary Note: Medikinet XL® – No new initiations from September 2026. Existing patients prescribed Medikinet XL should be switched to Ambinet XL at an appropriate clinical review. |
| NALTREXONE (UPDATED) | Yellow | For use in opioid dependency |
To be initiated and managed by specialists for maintenance treatment to help prevent relapse in opioid dependence in line with NICE TA 115. There is currently no commissioned service within general practice to support the prescribing and ongoing management of this treatment. Naltrexone may provide clinical benefit as a maintenance treatment to help prevent relapse in opioid dependence, so where a clinician has the appropriate expertise and feels clinically competent to do so, they may choose to prescribe. However, there is no contractual requirement or expectation for GPs to initiate or continue prescribing, and practices are not obligated to issue these prescriptions.
|
| NIRSEVIMAB (NEW) | Red | RSV passive immunisation as per green book | |
| Relugolix (Orgovyx®) (UPDATED) | Yellow | For treating hormone sensitive prostate cancer |
|
| SEMAGLUTIDE (Rybelsus®) | Green | Type 2 diabetes |
In line with NICE NG28 |
| TIRZEPATIDE (Mounjaro®) (UPDATED) | Yellow | For treating type 2 diabetes |
Once weekly preparation available only in line with NICE NG28 Not to be used alongside DPP-4 inhibitors First choice GLP-1 RA for T2DM new starts where BMI < 35 – SC semaglutide (Ozempic) First choice GLP-1 RA for T2DM new starts where BMI > 35 – SC semaglutide (Ozempic) or SC tirzepatide (Mounjaro) |
Other Updates on this Website
Recent documents from LLR APC and TAS
LLR APC Meeting Minutes July 2026(423 KB) - LMSG/LLR APC minutes
Date added: 10th Aug 2026
LLRAPC Newsletter – July 2026(459 KB) - LMSG/LLR APC newsletters
Date added: 6th Aug 2026
Patient choice for dispensing of continence and stoma appliances(143 KB)
Date added: 5th Aug 2026
Cellulitis Teicoplanin Pathway(1 MB) - Guidelines
Date added: 21st Jul 2020
Recording Medicines Prescribed And Issued By Other Healthcare Providers(411 KB) - Guidelines
Date added: 9th Mar 2018
About the Leicester, Leicestershire and Rutland Area Prescribing Committee
In common with other local health communities, the Leicester, Leicestershire and Rutland Area Prescribing Committee (LLR APC) acknowledges the benefits of having a Leicestershire Health Community-wide strategy for the prescribing of specialist medicines and the managed entry of new drugs and related technologies.
Leicestershire Health Community comprises the Leicester, Leicestershire and Rutland Integrated Care Board, University Hospitals of Leicester (UHL) NHS Trust and Leicestershire Partnership NHS Trust (LPT), amongst which there is a total consensus on the need for this strategy, and the LLR APC has been in place since 2005. Learn more